Research method
HPLC
7 studies
High-performance liquid chromatography separates a mixture on a column so that each peak can be quantified by UV, fluorescence or a mass spectrometer. Retention time plus a detector response is an assay of how much of a defined analyte is present, or a preparative cut of a labelled peptide — not a structure of an unseparated solid. In this library HPLC (and LC–MS/MS) maps mRNA fragments, measures PAH activity in a polymer film, isolates CF₃-labelled insulin, validates a kinase-inhibitor concentration, and serves as the reference method for a fluorescent fluoroquinolone probe.
Chemists reach for HPLC when they need to know how much of a species survived a reaction, an extraction, or a biological matrix. It answers 'did this peak separate, and how much is there?' Its main limitation is that coverage is not 100%, a fluorescence probe calibrated against HPLC-UV may not speciate mixtures, and an in vitro microsomal half-life is not a patient pharmacokinetic curve.
Studies
7
Findings
6
7 supporting · 0 challenging · 0 qualifying citations
Open tensions
2
Currently
What we know
- Partial RNase T1 digestion plus ion-pair reversed-phase LC–MS/MS can map large RNAs better than a complete digest. From 20–40 μg RNA (2–15 min, 37 or 60 °C), a single partial digest gives >80% sequence coverage of large RNAs/mRNA therapeutics, with few matches to random control sequences. Coverage is not 100%; complete T1 maps remain complementary, and a GMP QC kit is future work.
- HPLC-fluorescence can turn a PDMS-film concentration into chemical activity of PAHs in soil. Vials coated with 3–12 μm PDMS were equilibrated 122 h with coal-tar contaminated soil; methanol extracts were quantified by HPLC-fluorescence and converted via methanol solubility calibrations. Linear CPDMS versus PDMS volume (r² > 0.90) for 7 PAHs confirmed equilibrium; LoQ was 0.1–2.5 μM in PDMS. The result is equilibrium activity in one test soil, not a multi-site toxicity trial.
- Preparative HPLC isolates a labelled biomolecule whose conversion on the crude mixture is only modest. Photoredox CF₃ transfer gives 78% mono-CF₃ on Ac-Tyr-NHMe; Asp–Tyr reaches 90% combined conversion; an MSD photoreactor gives 61% combined isolated-scale yield (Kessil 39%). Insulin labelled at all four tyrosines (~30% conversion) afforded A19-CF₃ insulin in 12% isolated yield after HPLC, still with nM insulin-receptor activity. Trp competes when present.
- A validated C18 MRM LC–MS/MS method (pemigatinib 488→401/186, flavopiridol IS) after acetonitrile precipitation from human liver microsomes has mean recovery 101.7 ± 4.48% with QCs at 5–400 ng mL⁻¹. In vitro t½ is 27.29 min and CLint is 25.4 μL min⁻¹ mg⁻¹, implying moderate hepatic extraction. No patient PK curves are reported.
- A fluorescent Ag/Au nanocluster assay can match HPLC-UV recoveries without matching HPLC's ability to speciate. Al³⁺ raises DIT@AgAuNC quantum yield from 3.28% to 12.89% and lifetime from 11.03 to 17.89 ns; LODs for CIP/NOR/ENR are 3.1, 3.8 and 4.4 nM with recoveries 94–106% (RSD < 4.09%) in 1.5 min in eggs, milk and urine versus HPLC-UV. The probe cannot distinguish mixed fluoroquinolones.
Largest unresolved question
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
Procedure
How it works
The main stages of the method. Specific protocols and analysis choices vary between studies.
Inject the mixture onto a column
A defined analyte, a digest, or a labelled peptide is loaded. What does not dissolve or does not elute never becomes a peak.
Separate by retention
Species spend different times on the stationary phase. Retention time is an identity hypothesis that still needs a detector and, often, a standard.
Detect by UV, fluorescence, or mass spectrometry
Each peak is quantified by a detector response. HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs.
Quantify against a standard, or collect a cut
How much survived a reaction, an extraction, or a biological matrix is read off a calibration, or a labelled peptide is isolated. Coverage is not 100%; a probe calibrated against HPLC-UV may still fail to speciate mixtures.
Do not treat a peak as a patient half-life
HPLC answers whether this peak separated, and how much is there. An in vitro microsomal t½ is not a patient pharmacokinetic curve, and matching recoveries does not make a fluorescent probe a chromatographic speciation method.
Common misconceptions
Greater than 80% sequence coverage means the mRNA is fully sequenced and GMP-ready.
A single partial T1 digest outperforms complete digestion for large RNAs but is not 100% coverage; complete maps remain complementary, and inter-lab GMP QC is still future work.
If a fluorescent probe's recoveries match HPLC-UV, it can replace HPLC for mixed analytes.
CIP/NOR/ENR LODs are 3.1–4.4 nM with 94–106% recoveries, but the probe cannot distinguish mixed fluoroquinolones and was not tested in blood. HPLC-UV remains the speciation reference.
An HPLC-validated microsomal t½ is a patient half-life.
Pemigatinib's 27.29 min in vitro t½ and 25.4 μL min⁻¹ mg⁻¹ CLint come from HLM after a method with 101.7% mean recovery. The authors treat that as moderate hepatic extraction and note in vivo TDM still needs future work.
Related
Claim ledger
What the evidence shows
Drawn from 7 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
Partial RNase T1 digestion plus ion-pair reversed-phase LC–MS/MS can map large RNAs better than a complete digest. From 20–40 μg RNA (2–15 min, 37 or 60 °C), a single partial digest gives >80% sequence coverage of large RNAs/mRNA therapeutics, with few matches to random control sequences. Coverage is not 100%; complete T1 maps remain complementary, and a GMP QC kit is future work.
HPLC-fluorescence can turn a PDMS-film concentration into chemical activity of PAHs in soil. Vials coated with 3–12 μm PDMS were equilibrated 122 h with coal-tar contaminated soil; methanol extracts were quantified by HPLC-fluorescence and converted via methanol solubility calibrations. Linear CPDMS versus PDMS volume (r² > 0.90) for 7 PAHs confirmed equilibrium; LoQ was 0.1–2.5 μM in PDMS. The result is equilibrium activity in one test soil, not a multi-site toxicity trial.
Preparative HPLC isolates a labelled biomolecule whose conversion on the crude mixture is only modest. Photoredox CF₃ transfer gives 78% mono-CF₃ on Ac-Tyr-NHMe; Asp–Tyr reaches 90% combined conversion; an MSD photoreactor gives 61% combined isolated-scale yield (Kessil 39%). Insulin labelled at all four tyrosines (~30% conversion) afforded A19-CF₃ insulin in 12% isolated yield after HPLC, still with nM insulin-receptor activity. Trp competes when present.
A validated C18 MRM LC–MS/MS method (pemigatinib 488→401/186, flavopiridol IS) after acetonitrile precipitation from human liver microsomes has mean recovery 101.7 ± 4.48% with QCs at 5–400 ng mL⁻¹. In vitro t½ is 27.29 min and CLint is 25.4 μL min⁻¹ mg⁻¹, implying moderate hepatic extraction. No patient PK curves are reported.
A fluorescent Ag/Au nanocluster assay can match HPLC-UV recoveries without matching HPLC's ability to speciate. Al³⁺ raises DIT@AgAuNC quantum yield from 3.28% to 12.89% and lifetime from 11.03 to 17.89 ns; LODs for CIP/NOR/ENR are 3.1, 3.8 and 4.4 nM with recoveries 94–106% (RSD < 4.09%) in 1.5 min in eggs, milk and urine versus HPLC-UV. The probe cannot distinguish mixed fluoroquinolones.
HPLC-adjacent assays in this set also include enzyme activity workups. E. coli DERA is irreversibly inactivated after 200–300 mM acetaldehyde; crotonaldehyde inhibits more than 100-fold more potently (1 mM, <1 h) via K167/C47; C47M keeps 60 ± 5% activity and loses none after 16 h in 300 mM acetaldehyde. LIMK2 PROTAC THNAN69 has DC₅₀ = 1 nM (versus 33 nM for analogue 21b) and 10 nM depletes endogenous LIMK2 — proteomics/Western, not a simple UV chromatogram, carry that selectivity claim.
Study Role Design N Population Outcome Why acetaldehyde kills the DERA aldolase Supports Animal / in-vitroCrystallography, 13C NMR, and a C47M mutant of E. coli DERA in concentrated acetaldehyde Enzyme kinetics and structures rather than a biological sample N E. coli deoxyribose-phosphate aldolase and orthologues Crotonaldehyde covalently inactivates DERA via K167–C47; C47M retains activity in 300 mM acetaldehyde PROTAC THNAN69 degrades LIMK2, not LIMK1 Supports Animal / in-vitroCRBN/VHL PROTACs of LIMKi3 ranked by cellular degradation and proteomics Cell-based degrader SAR (e.g., HuCCT1 EGFP–LIMK2 / Western blot) — no subject N Cultured cells expressing LIMK2 (including HuCCT1) LIMK2-selective degradation potency (THNAN69 DC50 ≈ 1 nM)
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
- MS sequence maps of mRNA using partial RNase T1
- PDMS vials measure PAH activity in polluted soil
- Protecting-group-free peptide CF3 labeling
Study Role Design N Population Outcome MS sequence maps of mRNA using partial RNase T1 Supports OtherImmobilized partial RNase T1 digestion with IP-RP LC–MS/MS for large RNA/mRNA mapping Analytical method on 20–40 μg RNA inputs — no biological cohort N Large RNAs and therapeutic mRNA samples Sequence coverage from partial vs complete T1 mapping (>80% from one partial digest) PDMS vials measure PAH activity in polluted soil Supports OtherPDMS-coated vials equilibrated with coal-tar contaminated soil to measure PAH chemical activity Single contaminated soil with multiple PDMS volumes; method development — no cohort N Coal-tar contaminated soil and PDMS passive samplers Chemical activity of PAHs via PDMS equilibrium concentrations Protecting-group-free peptide CF3 labeling Supports OtherRadical CF3 labeling of unprotected peptides and insulin with photoredox or zinc sulfinate conditions Peptide chemistry with secondary receptor-binding assays — no subject cohort N Model peptides, hormones, and insulin Site-selective tyrosine trifluoromethylation yields and retained insulin activity
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Agreement with HPLC-UV recoveries does not mean the new assay is HPLC. The Ag/Au cluster probe matches 94–106% recoveries in 1.5 min but cannot speciate mixed FQs, which a chromatographic method is built to do. Pemigatinib LC–MS/MS recovery 101.7% is a validated concentration assay in HLM, not a 1.5 min optical screen.
Agreement with HPLC-UV recoveries does not mean the new assay is HPLC. The Ag/Au cluster probe matches 94–106% recoveries in 1.5 min but cannot speciate mixed FQs, which a chromatographic method is built to do. Pemigatinib LC–MS/MS recovery 101.7% is a validated concentration assay in HLM, not a 1.5 min optical screen.
- Al3+ lights up Ag/Au clusters to sense fluoroquinolones
- LC-MS/MS assay and microsomal half-life of pemigatinib
Study Role Design N Population Outcome Al3+ lights up Ag/Au clusters to sense fluoroquinolones Supports OtherDIT@AgAuNC fluorescence probe with Al3+ AIE for fluoroquinolone quantification vs HPLC Analytical method validated in eggs, milk, and urine — no subject cohort N Food and urine matrices spiked with ciprofloxacin, norfloxacin, and enrofloxacin Nanomolar LODs and recoveries for fluoroquinolone determination LC-MS/MS assay and microsomal half-life of pemigatinib Supports OtherValidated C18 MRM LC-MS/MS of pemigatinib in human liver microsomes with well-stirred clearance model Bioanalytical method validation and in-vitro HLM kinetics — no subject N Human liver microsome incubations of pemigatinib Quantification performance and in-vitro t½ / CLint of pemigatinib
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
- PROTAC THNAN69 degrades LIMK2, not LIMK1
Concept page published
HPLC
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
- Coverage updated · Concept page published
Papers
7 studies in this library bear on HPLC, ordered by citations.
- Protecting-group-free peptide CF3 labeling
ZnTFMS/TBHP or Ir photoredox trifluoromethylates tyrosine C–H on unprotected peptides, including insulin, without hitting polar side chains.
- PDMS vials measure PAH activity in polluted soil
Thin PDMS coatings of several thicknesses in glass vials reach equilibrium with soil PAHs so HPLC-fluorescence concentrations can be converted into chemical activities.
- MS sequence maps of mRNA using partial RNase T1
A short digest with bead-bound RNase T1 plus tandem MS covers more than 80% of long mRNA sequences in one run, beating complete T1 maps.
- LC-MS/MS assay and microsomal half-life of pemigatinib
A two-minute LC-MS/MS method quantifies pemigatinib in human liver microsomes and finds a 27.29 min half-life and moderate CLint.
- Why acetaldehyde kills the DERA aldolase
Crotonaldehyde, the acetaldehyde aldol product, covalently bridges catalytic K167 to nearby C47; a C47M mutant survives 300 mM acetaldehyde.
- Al3+ lights up Ag/Au clusters to sense fluoroquinolones
Dithioerythritol Ag/Au nanoclusters aggregate with Al3+ and then report ciprofloxacin, norfloxacin and enrofloxacin by ratiometric fluorescence down to a few nanomolar.
- PROTAC THNAN69 degrades LIMK2, not LIMK1
A cereblon-recruiting degrader based on LIMKi3 and a phenyl dihydrouracil ligand wipes out LIMK2 at nanomolar DC50 while leaving LIMK1 and phospho-cofilin largely intact.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
Agreement with HPLC-UV recoveries does not mean the new assay is HPLC. The Ag/Au cluster probe matches 94–106% recoveries in 1.5 min but cannot speciate mixed FQs, which a chromatographic method is built to do. Pemigatinib LC–MS/MS recovery 101.7% is a validated concentration assay in HLM, not a 1.5 min optical screen.
Study this conceptflashcards and short-answer questions
Why can a partial RNase T1 digest give higher than 80% mRNA coverage while a complete T1 map is still worth running?
Partial digestion produces longer, more unique oligoribonucleotides that LC–MS/MS can place on the sequence; complete digestion can over-fragment and lose coverage. Coverage is still not 100%, so the two maps are complementary rather than redundant.
PDMS vials give linear CPDMS versus polymer volume (r² > 0.90) for seven PAHs. What does that linearity buy you, and what does HPLC-fluorescence still not measure?
Linearity versus PDMS volume supports equilibrium partitioning into 3–12 μm films after 122 h. HPLC-fluorescence then quantifies the methanol extract (LoQ 0.1–2.5 μM in PDMS). That is chemical activity in one soil, not a bioavailability/toxicity trial.
Insulin CF₃ labelling is ~30% conversion yet A19-CF₃ insulin is isolated in 12% yield. What is HPLC doing in that gap?
The crude mixture contains multiple tyrosine-labelled species. HPLC separates them so that one regioisomer can be isolated (12%) and then tested for receptor activity. Conversion on all four tyrosines is not the isolated yield of one product.
A nanocluster assay reports 94–106% recovery versus HPLC-UV in 1.5 min. When must you still run HPLC?
When the sample may contain mixed ciprofloxacin, norfloxacin and enrofloxacin: the probe cannot speciate overlapping FQs. HPLC-UV (or LC–MS) is the method that separates them; the optical assay is a fast sum signal with nM LODs.